➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Medtronic
Harvard Business School
Mallinckrodt
Boehringer Ingelheim

Last Updated: August 6, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CANCIDAS

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Cancidas

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00105144 Study of Micafungin in Patients With Invasive Candidiasis or Candidemia Completed Astellas Pharma Inc Phase 3 2004-09-01 The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.
NCT00388167 Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection Completed GTEI Phase 4 2004-03-01 We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole).
NCT00388167 Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection Completed SEMICYUC Phase 4 2004-03-01 We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole).
NCT00388167 Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection Completed PETHEMA Foundation Phase 4 2004-03-01 We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole).
NCT00404092 Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis Completed University of Cologne Phase 2 2006-10-01 This study investigates the safety and tolerability as well as the efficacy and pharmacokinetics of caspofungin in four escalating dosages in adult patients with hematologic malignancies and proven or probable invasive aspergillosis.
NCT00413218 Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections Completed Basilea Pharmaceutica Phase 3 2006-12-01 The purpose of the study is to compare the safety and efficacy of Isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.
NCT00413218 Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections Completed Astellas Pharma Inc Phase 3 2006-12-01 The purpose of the study is to compare the safety and efficacy of Isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cancidas

Condition Name

Condition Name for Cancidas
Intervention Trials
Mycoses 5
Fungal Infection 5
Candidemia 5
Fungemia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cancidas
Intervention Trials
Mycoses 12
Infection 6
Candidiasis 6
Candidemia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cancidas

Trials by Country

Trials by Country for Cancidas
Location Trials
United States 69
Spain 14
Canada 13
Brazil 8
China 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cancidas
Location Trials
Michigan 5
Alabama 4
Pennsylvania 3
Ohio 3
New York 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cancidas

Clinical Trial Phase

Clinical Trial Phase for Cancidas
Clinical Trial Phase Trials
Phase 4 4
Phase 3 6
Phase 2 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cancidas
Clinical Trial Phase Trials
Completed 9
Recruiting 3
Unknown status 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cancidas

Sponsor Name

Sponsor Name for Cancidas
Sponsor Trials
Astellas Pharma Inc 3
Pfizer 2
Merck Sharp & Dohme Corp. 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cancidas
Sponsor Trials
Other 12
Industry 12
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Harvard Business School
Medtronic
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.